

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Bulevirtide for treating chronic hepatitis D [ID3732]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, one stakeholder noted stigma associated with hepatitis B and D virus (HBV/HDV). Please see the scope consultation comments for full details. In addition, stakeholders commented that some communities are endemic for HBV, including some African, Asian and other groups, and they may have higher prevalence of HBV/HDV coinfection.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Race is a protected characteristic under equality legislation. These potential equality issues will be presented to the committee for consideration. Preliminary view that no adjustments are needed in relation to these potential equality issues. This is because it is not expected that the appraisal will discriminate against people sharing these characteristics, as the population considered in this appraisal is 'adults with chronic hepatitis D'.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** Henry Edwards

**Date:** 09/03/2021